Global Neurosarcoidosis Treatment Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neurosarcoidosis Treatment Market Insights, Forecast to 2034
Neurosarcoidosis is the type of chronic inflammatory disease that is characterized by the formation of granulomas. It affects several parts of the body and internal organs such as lungs, brain, lymph nodes, spinal cord and others. Patients suffering from confusion, headaches, inability or change in ability to smell or taste, psychiatric issues, seizures, hallucinations, and speech difficulties are the majorly susceptible to this condition.
Global Neurosarcoidosis Treatment market is expected to reach to US$ 5590 million in 2024, with a positive growth of %, compared with US$ 5370 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Neurosarcoidosis Treatment industry is evaluated to reach US$ 7114 million in 2029. The CAGR will be 4.1% during 2024 to 2029.
Sarcoidosis is a worldwide disease affecting all races, ages, and genders. 70% of patients are between 25 and 45 years old. In Europe and Japan, women over the age of 50 are the second highest incidence of sarcoidosis. The onset is rare in those younger than 15 or older than 70. Most studies show that the prevalence of women is slightly higher, and the incidence rate is increasing. The average onset age of NS is between 33 and 41 years old, which is later than other types of sarcoidosis. About 50% of patients have systemic diseases, and 30%-70% have neurological symptoms. All systems of sarcoidosis have a mortality rate of 1% to 5% due to pulmonary, cardiac, or neurologic involvement.
Report Covers
This report presents an overview of global Neurosarcoidosis Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Neurosarcoidosis Treatment market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Hikma Pharmaceuticals PLC
Mylan N.V.
Amneal Pharmaceuticals LLC
Mallinckrodt
AbbVie Inc
Pfizer Inc
Sandoz International GmbH
Teva Pharmaceuticals
F. Hoffmann-La Roche Ltd
Fresenius Kabi USA
Merck & Co.，Inc
Vintage Labs
Taro Pharmaceutical Industries Ltd
Jubilant Cadista Pharmaceuticals Inc
Horizon Therapeutics plc
Segment by Type
Oral
Extraintestinal
Hospitals
Specialty Clinics
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Neurosarcoidosis Treatment plant distribution, commercial date of Neurosarcoidosis Treatment, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Neurosarcoidosis Treatment introduction, etc. Neurosarcoidosis Treatment Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Neurosarcoidosis Treatment
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Neurosarcoidosis Treatment market is expected to reach to US$ 5590 million in 2024, with a positive growth of %, compared with US$ 5370 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Neurosarcoidosis Treatment industry is evaluated to reach US$ 7114 million in 2029. The CAGR will be 4.1% during 2024 to 2029.
Sarcoidosis is a worldwide disease affecting all races, ages, and genders. 70% of patients are between 25 and 45 years old. In Europe and Japan, women over the age of 50 are the second highest incidence of sarcoidosis. The onset is rare in those younger than 15 or older than 70. Most studies show that the prevalence of women is slightly higher, and the incidence rate is increasing. The average onset age of NS is between 33 and 41 years old, which is later than other types of sarcoidosis. About 50% of patients have systemic diseases, and 30%-70% have neurological symptoms. All systems of sarcoidosis have a mortality rate of 1% to 5% due to pulmonary, cardiac, or neurologic involvement.
Report Covers
This report presents an overview of global Neurosarcoidosis Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Neurosarcoidosis Treatment market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Hikma Pharmaceuticals PLC
Mylan N.V.
Amneal Pharmaceuticals LLC
Mallinckrodt
AbbVie Inc
Pfizer Inc
Sandoz International GmbH
Teva Pharmaceuticals
F. Hoffmann-La Roche Ltd
Fresenius Kabi USA
Merck & Co.，Inc
Vintage Labs
Taro Pharmaceutical Industries Ltd
Jubilant Cadista Pharmaceuticals Inc
Horizon Therapeutics plc
Segment by Type
Oral
Extraintestinal
Segment by Application
Hospitals
Specialty Clinics
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Neurosarcoidosis Treatment plant distribution, commercial date of Neurosarcoidosis Treatment, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Neurosarcoidosis Treatment introduction, etc. Neurosarcoidosis Treatment Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Neurosarcoidosis Treatment
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices